Antibody Slows Beta-Cell Loss Early in Type 1 Diabetes

(MedPage Today) -- A course of teplizumab (Tzield) may help preserve beta-cells when given early after a type 1 diabetes (T1D) diagnosis, similar to the anti-CD3 antibody's delay on progression from preclinical disease, the randomized PROTECT trial...
Source: MedPage Today Pediatrics - Category: Pediatrics Source Type: news